Irish medical technology firm Medtronic has partnered with BD Medical to launch a new insulin pump infusion set, which is being developed using BD FlowSmart technology.

Under the deal, Medtronic will take responsibility to commercialize the infusion set, while BD will manufacture the product.

BD Medical-Diabetes Care worldwide president Kenneth Miller said: "We are very excited to partner with a global leader like Medtronic to ensure that the benefits of BD FlowSmart technology can be made widely available to as many people living with diabetes as possible."

According to Medtronic, the infusion set recently obtained FDA and Health Canada approval and is expected to be introduced in 2016.

The insulin infusion set with BD FlowSmart technology has been developed in partnership with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust to enhance the treatment options for type 1 diabetes.

An application was submitted for CE mark approval of the product, which has been designed to work with both Medtronic insulin pumps and most other manufacturers’ insulin pumps.

The insulin infusion set with BD FlowSmart technology includes a unique side-ported catheter that helps to improve insulin flow and reduce number of flow interruptions. It also features the smallest insertion needle (30 gauge) that is designed to reduce insertion pain.